The FDA has conducted a comprehensive review of the benefits and risks of using LABAs to treat asthma. Drs. Badrul Chowdhury and Gerald Dal Pan discuss the agency's conclusions.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: